Press releases
Sanitas earned gross profit of LTL 210,6 million last year Information to mass communications February 27, 2009 The largest Lithuanian pharmaceutical company Sanitas, which also controls the Slovakian pharmaceutical plant Hoechst-Biotika and Polish pharmaceutical companies Jelfa and Laboratorium Farmaceutyczne HOMEOFARM, made the consolidated sales in LTL 382,5 million (according to the non-audited data) and earned the gross profit of LTL 210,6 million last year. Due to the variations of currency rates the net loss of this period made LTL 2,1 million. The profit of the group before interest, taxes, depreciation and amortization in 2008 made LTL 90,2 million. In the last quarter of the year 2008 the profit of Sanitas group before interest, taxes, depreciation and amortization made LTL 16,5 million. During this period the net loss in LTL 17,5 million was suffered. According to the representatives of Sanitas, the main cause of the losses is the loss in currency rate formed due to the weakened Polish zloty. In total in 2008 the Sanitas group suffered the losses in LTL 49,9 million because of the influence of the currency rates, where the loss of LTL 43,4 million was suffered in the last quarter of the year 2008. Following the changed situation in the international markets the group formed additional extensions in LTL 3,1 millions for the amounts receivable from the clients, who work in the risky markets (mainly in and ) in the last quarter of the year 2008. According to the Financial Director of Sanitas, Nerijus Drobavičius, as the risk of insolvency of the clients acting in the risky markets has increased the Sanitas group has toughened the sale conditions for them. This had negative impact on the sales in the last quarter of the year 2008; however, it was necessary means in order to prevent the insolvency of such clients. The main shareholders of the company Sanitas are the investment company Invalda and investment funds Amber Trust II SCA and Citigroup Venture Capital International Jersey. The shares of Sanitas are quoted on the Official trade list of the “NASDAQ OMX Vilnius” Ltd. Stock Exchange. Further information can be obtained at: Nerijus Drobavičius, Financial Director of Sanitas Cell phone: 8 686 93969 Sanitas acquired Polish company Homeofarm Press release 23 12 2008 Sanitas, the biggest Lithuanian drug maker, acquired 100% of shares in Polish ointment producer Homeofarm for PLN 10.9 mio. The transaction was executed between Sanitas’ subsidiary Jelfa and company Hand-Prod. Vienna Capital Partners acted as the exclusive investment banking advisor to Hand Prod. Homeofarm production facilities are located in “Homeofarm product portfolio nicely fits to our business development strategy. Some products we were developing in-house and this acquisition will let us complete our dermatological portfolio faster,” the CEO of Sanitas Saulius Jurgelenas said. “We see a lot of synergies to be utilised in 2009,” added Mr. Jurgelenas The main shareholders of Sanitas are the investment company Invalda and investment funds Amber Trust II SCA and Citigroup Venture Capital International Jersey. The shares of Sanitas are quoted on the Official list of the Vilnius Stock Exchange.
Sanitas is opening a new pharmaceutical plant Information to mass communications 23 September 2008 The largest Lithuanian pharmaceutical company Sanitas, which also controls the Slovakian pharmaceutical plant Hoechst-Biotika and Polish pharmaceutical company Jelfa, on Tuesday opened the new plant in “It is natural that the manufacturing development did not have any future in the center of According to him, the capacity of the new plant with almost 190 employees should reach 300 mln. pills, 50 mln. capsules, 50 mln. ampoules per year, while 15 mln. of each eye drops and onetime syringes filled with medications should be made. The project was started in 2005. The resources of the EU structural funds – 16,1 mln. litas were used. The total value of the project reached 68 mln. litas. It is planned to start the manufacture in the new plant in November when all the certification formalities are completed. The main shareholders of the company Sanitas are the investment company Invalda and investment funds Amber Trust II SCA and Citigroup Venture Capital International Jersey. The shares of Sanitas are quoted on the Official list of the Vilnius Stock Exchange. Further information can be obtained at: Saulius Jurgelėnas, Director General of Sanitas Phone (8 37) 22 67 25, mob. 8 686 67779
The consolidated pre-tax profit of Sanitas in the first half-year – LTL 21,468 million Information to mass communications 18 August 2008 The largest Lithuanian pharmaceutical company Sanitas, which also controls the Slovakian pharmaceutical plant Hoechst-Biotika and Polish pharmaceutical company Jelfa, made the consolidated pre-tax profit in this first half-year in the amount of LTL 21,468 million, and the sales made LTL 193,629 million.
In the same period last year the consolidated pre-tax profit made LTL 28,6 million, and the sales made LTL 166,799 million. According to Mr. Saulius Jurgelėnas, Director General of Sanitas, the pre-tax profit was a little smaller this year than expected. This was mainly influenced by the increased financial costs and sales in US dollars in the beginning of the year. The profit of Sanitas before interest, taxes, depreciation and amortization (EBITDA) in the first half-year reached LTL 57,422 million, and in the same period last year it made LTL 59,411 million. According to Mr. S. Jurgelėnas, the second half-year is going to be much more successful than the last year. “Last quarter we stopped the old plant in The sales of Sanitas have increased the most in the first six months of the year in Poland (LTL 12,9 million more than in the same period last year) and in Russia (LTL 8,9 million more than in the same period last year), where the team in the company’s office in Moscow has been strengthened. The majority of the sales in the first half-year consisted of ointments (38 percent of sales), pills and capsules (33 percent of all sales), while the sales of the solutions for injections made 29 percent of all sales. The main shareholders of the company Sanitas are the investment company Invalda and investment funds Amber Trust II SCA and Citigroup Venture Capital International Jersey. The shares of Sanitas are quoted on the Official list of the Vilnius Stock Exchange.
Further information can be obtained at: Saulius Jurgelėnas, Director General of Sanitas Phone (8 37) 22 67 25, mob. 8 686 67779 Part of Sanitas employees will be motivated by company’s shares Press release 19.06.2008 Part of the employees of Sanitas, the largest pharmaceutical company in , and part of employees of pharmaceutical plant Hoechst-Biotika and the Polish pharmaceutical producer Jelfa, both controlled by Sanitas, will have an opportunity to acquire shares of Sanitas. During the Sanitas General Shareholders Meeting which will take place on Ju
After the full distribution of the new shares emission, the total amount of which is LTL 12 million, the authorized capital of Sanitas would increase to 31 855 920.
According to Darius Sulnis, the chairman of Sanitas Management Board, the shareholders of the company clear
“We have to take into account that review of Sanitas strategic alternatives is being performed and possibilities to increase company‘s value are being ana
Investment company Invalda as well as investment funds Amber Trust II SCA and Citigroup Venture Capital International Jersey are the main shareholders of Sanitas. Sanitas’ shares are quoted on the Main List of the Vilnius Stock Exchange. For more information please contact: Darius Sulnis, the chairman of Sanitas Management Board, mob. tel. +370 698 34781